IFI35

Summary

IFI35 (interferon induced protein 35, HGNC:5399) is a protein-coding gene on chromosome 17q21.31, encoding Interferon-induced 35 kDa protein (P80217). Acts as a signaling pathway regulator involved in innate immune system response.

Enables identical protein binding activity. Involved in several processes, including macrophage activation involved in immune response; negative regulation of non-canonical NF-kappaB signal transduction; and positive regulation of defense response. Located in several cellular components, including cytosol; extracellular space; and nuclear lumen.

Source: NCBI Gene 3430 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_001330230

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5399
Approved symbol	IFI35
Name	interferon induced protein 35
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	IFP35
Ensembl gene	ENSG00000068079
Ensembl biotype	protein_coding
OMIM	600735
Entrez	3430

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 5 retained_intron, 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000246911, ENST00000396722, ENST00000415816, ENST00000438323, ENST00000534876, ENST00000536969, ENST00000538473, ENST00000546325

RefSeq mRNA: 2 — MANE Select: NM_001330230 NM_001330230, NM_005533

CCDS: CCDS11450, CCDS82134

Canonical transcript exons

ENST00000415816 — 7 exons

Exon	Start	End
ENSE00000727548	43013776	43013882
ENSE00001288037	43013476	43013662
ENSE00002253201	43006784	43006968
ENSE00003484492	43013267	43013373
ENSE00003512509	43012179	43012277
ENSE00003576323	43013047	43013194
ENSE00003900407	43014108	43014456

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 96.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.0161 / max 359.3059, expressed in 1733 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161042	15.3829	1717
161043	3.3794	939
161044	0.1524	62
161045	0.1014	47

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	96.81	gold quality
monocyte	CL:0000576	96.43	gold quality
mononuclear cell	CL:0000842	96.26	gold quality
leukocyte	CL:0000738	96.13	gold quality
decidua	UBERON:0002450	95.12	gold quality
right adrenal gland	UBERON:0001233	94.92	gold quality
right adrenal gland cortex	UBERON:0035827	94.30	gold quality
left adrenal gland cortex	UBERON:0035825	94.14	gold quality
left adrenal gland	UBERON:0001234	94.13	gold quality
mucosa of transverse colon	UBERON:0004991	93.73	gold quality
apex of heart	UBERON:0002098	93.68	gold quality
adrenal cortex	UBERON:0001235	92.73	gold quality
spleen	UBERON:0002106	92.68	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.57	gold quality
gall bladder	UBERON:0002110	92.31	gold quality
adrenal gland	UBERON:0002369	91.96	gold quality
transverse colon	UBERON:0001157	91.54	gold quality
upper lobe of left lung	UBERON:0008952	91.52	gold quality
tibial nerve	UBERON:0001323	91.48	gold quality
omental fat pad	UBERON:0010414	91.29	gold quality
peritoneum	UBERON:0002358	91.24	gold quality
small intestine	UBERON:0002108	91.07	gold quality
muscle layer of sigmoid colon	UBERON:0035805	91.05	gold quality
tendon of biceps brachii	UBERON:0008188	90.96	gold quality
mucosa of stomach	UBERON:0001199	90.88	gold quality
blood	UBERON:0000178	90.84	gold quality
right ovary	UBERON:0002118	90.80	gold quality
vermiform appendix	UBERON:0001154	90.74	gold quality
adipose tissue of abdominal region	UBERON:0007808	90.74	gold quality
left ovary	UBERON:0002119	90.73	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	165.66
E-HCAD-13	yes	13.20
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, IRF1, IRF2, STAT1

miRNA regulators (miRDB)

17 targeting IFI35, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-589-5P	98.72	66.96	927
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-3155A	98.16	66.09	965
HSA-MIR-3155B	98.16	66.09	965
HSA-MIR-484	98.16	66.92	1074
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-5189-5P	97.72	66.96	1814
HSA-MIR-612	97.26	65.95	1597
HSA-MIR-6860	97.21	66.31	1656

Literature-anchored findings (GeneRIF, showing 14)

• Dissociation of the IFN-induced protein IFP35 from NMI is a newly defined specific cytoplasmic event occurring during apoptosis. (PMID:11911807)
• The results provide a novel role of CKIP-1 in cytokine signaling response and the biochemical mechanism, by which two previously identified modulators IFP35 and Nmi are involved via interactions. (PMID:17197158)
• IFP35 can interact with the bovine Tas (BTas) regulatory protein of bovine foamy virus; overexpression of IFP35 disturbs the ability of BTas to activate viral-gene transcription and inhibits viral replication. (PMID:18305040)
• IRF-1 also activates IFP35 expression in an IFN-gamma-inducible manner. (PMID:23226549)
• IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication. (PMID:24371060)
• Knockdown of IFP35 expression abolished pEGFP-N1-2C and pEGFP-N1-Nmi-induced activation of type I interferon promoters. (PMID:25085622)
• Trim21 regulates Nmi-IFI35 complex-mediated inhibition of innate antiviral response (PMID:26342464)
• Activation of TLR3 by poly IC induces the IFI35 expression in Mesangial Cells. Regional expression of IFI35 and its dysregulation may be involved in the pathogenesis of glomerular inflammation in CKD. (PMID:27639618)
• IFI35 enhances proliferation of mesangial cells and is regulated by MBD2 in lupus nephritis. (PMID:28064541)
• Study found that TLR3 signaling induces the expression of IFI35, and IFI35 negatively regulates IFN-beta-P-STAT1-RIG-I-CXCL10/CCL5 axis in U373MG cells. This suggests that IFI35 expressed in astrocytes may play an important role in regulating the innate immune system in astrocytoma cells. (PMID:28109979)
• Damage-associated molecular patterns (DAMP) are important mediators of innate immunity. Here the authors show that N-myc and STAT interactor (NMI) and interferon-induced protein 35 (IFP35) act as DAMPs to promote inflammation by activating macrophages via the Toll-like receptor 4 and NF-kappaB pathways. (PMID:29038465)
• inhibits both endothelial cell proliferation and migration by inhibiting the NF-kappaB/p65 pathway; functionally interacts with Nmi through its NID1 domain (PMID:29350881)
• IFI35 as a biomolecular marker of neuroinflammation and treatment response in multiple sclerosis. (PMID:32781067)
• IFP35 family proteins promote neuroinflammation and multiple sclerosis. (PMID:34362845)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifi35	ENSDARG00000075643
mus_musculus	Ifi35	ENSMUSG00000010358
rattus_norvegicus	Ifi35	ENSRNOG00000020678

Paralogs (2): NMI (ENSG00000123609), RBM43 (ENSG00000184898)

Protein

Protein identifiers

Interferon-induced 35 kDa protein — P80217 (reviewed: P80217)

All UniProt accessions (1): P80217

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a signaling pathway regulator involved in innate immune system response. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation. In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production. In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion. Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines.

Subunit / interactions. Homodimer. Also interacts with BATF. Interacts with TRIM21. Interacts with NMI; the interaction is direct and is facilitated by TRIM21.

Subcellular location. Cytoplasm. Nucleus. Secreted.

Tissue specificity. Expressed in a wide range of cell types, including fibroblasts, macrophages, and epithelial cells.

Post-translational modifications. Phosphorylated. Dephosphorylation correlates with the formation of a complex with NMI.

Domain organisation. The NID domain 1 is involved in the negative regulation of p65/RELA transcription and the negative regulation of NF-kappa-B pathway activation.

Induction. Up-regulated by interferons IFN-alpha and IFN-gamma.

Miscellaneous. Due to a polymorphism at the 3’-splice acceptor site of intron 4.

Similarity. Belongs to the NMI family.

Isoforms (2)

UniProt ID	Names	Canonical?
P80217-1	1	yes
P80217-2	2

RefSeq proteins (2): NP_001317159, NP_005524 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009909	Nmi/IFP35_dom	Domain
IPR009938	Nmi/IFP35_N	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily

Pfam: PF07292, PF07334

UniProt features (9 total): domain 2, sequence variant 2, initiator methionine 1, chain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
21NG	X-RAY DIFFRACTION	1.53
21OT	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P80217-F1	83.45	0.48

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-168256	Immune System
R-HSA-913531	Interferon Signaling

MSigDB gene sets: 383 (showing top): JI_RESPONSE_TO_FSH_UP, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_MACROPHAGE_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, MODULE_45, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_REGULATION_OF_TOLL_LIKE_RECEPTOR_4_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN, CHANG_IMMORTALIZED_BY_HPV31_DN, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS

GO Biological Process (10): macrophage activation involved in immune response (GO:0002281), negative regulation of cell population proliferation (GO:0008285), positive regulation of toll-like receptor 4 signaling pathway (GO:0034145), innate immune response (GO:0045087), positive regulation of innate immune response (GO:0045089), positive regulation of inflammatory response (GO:0050729), negative regulation of non-canonical NF-kappaB signal transduction (GO:1901223), positive regulation of non-canonical NF-kappaB signal transduction (GO:1901224), immune system process (GO:0002376), regulation of innate immune response (GO:0045088)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Interferon Signaling	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
immune response	2
positive regulation of defense response	2
positive regulation of response to external stimulus	2
innate immune response	2
non-canonical NF-kappaB signal transduction	2
regulation of non-canonical NF-kappaB signal transduction	2
nuclear lumen	2
myeloid cell activation involved in immune response	1
leukocyte activation involved in immune response	1
macrophage activation	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
toll-like receptor 4 signaling pathway	1
regulation of toll-like receptor 4 signaling pathway	1
positive regulation of pattern recognition receptor signaling pathway	1
defense response to symbiont	1
positive regulation of response to biotic stimulus	1
regulation of innate immune response	1
positive regulation of immune response	1
inflammatory response	1
regulation of inflammatory response	1
negative regulation of intracellular signal transduction	1
positive regulation of intracellular signal transduction	1
biological_process	1
regulation of response to biotic stimulus	1
regulation of defense response	1
regulation of response to external stimulus	1
regulation of immune response	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

2763 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFI35	IFITM3	Q01628	721
IFI35	RND2	P52198	716
IFI35	IRF1	P10914	678
IFI35	STAT2	P52630	675
IFI35	IFIT3	O14879	673
IFI35	IFIT1	P09914	670
IFI35	NBR1	Q14596	669
IFI35	PSMB8	P28062	668
IFI35	IFI44	Q8TCB0	664
IFI35	IFITM1	P13164	661
IFI35	IFI6	P09912	655
IFI35	OAS1	P00973	621
IFI35	ISG15	P05161	619
IFI35	IFI27	P40305	619
IFI35	CREB3	O43889	614

IntAct

15 interactions, top by confidence:

A	B	Type	Score
CLEC4G	IFI35	psi-mi:“MI:0915”(physical association)	0.540
IFI35	CLEC4G	psi-mi:“MI:0915”(physical association)	0.540
IFI35	CLEC4G	psi-mi:“MI:0403”(colocalization)	0.540
PHF19	EPOP	psi-mi:“MI:0914”(association)	0.530
FCN1	IFI35	psi-mi:“MI:0915”(physical association)	0.370
IFI35	KDM1A	psi-mi:“MI:0915”(physical association)	0.370
IFI35	TFAP2A	psi-mi:“MI:0915”(physical association)	0.370
NMI	TARS3	psi-mi:“MI:0914”(association)	0.350
IFI35	CYTH3	psi-mi:“MI:0914”(association)	0.350
IFI35	MAPK1	psi-mi:“MI:0915”(physical association)	0.000
IFI35	PLEKHO1	psi-mi:“MI:0915”(physical association)	0.000
CLEC4G	IFI35	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (51): IFI35 (Affinity Capture-MS), TRIM21 (Affinity Capture-MS), TRIM21 (Affinity Capture-Western), NMI (Affinity Capture-Western), IFI35 (Affinity Capture-Western), NMI (Two-hybrid), IFI35 (Affinity Capture-MS), IFI35 (Affinity Capture-Western), IFI35 (Two-hybrid), FHL2 (Two-hybrid), BCAS2 (Two-hybrid), NMI (Two-hybrid), EML2 (Two-hybrid), IFI35 (Two-hybrid), IFI35 (Two-hybrid)

ESM2 similar proteins: A0A1B0GUJ8, A0JPF9, A5A6J9, A6H5X4, B1ARD8, E1C3S7, F6QZ15, G1SRW8, O14862, O14879, O35309, O95256, P0C7P3, P80217, Q13287, Q14B46, Q1LZ50, Q2EMV9, Q2T9U5, Q3B7D9, Q3ZCL3, Q460N5, Q4R7Q1, Q5I0E2, Q5I0J8, Q5RCZ8, Q5XGX5, Q5XIZ9, Q6IEE8, Q6NVF4, Q6ZSC3, Q80VH0, Q8BVM9, Q8C8H8, Q8CAS9, Q8IXQ6, Q8IYM2, Q91VJ1, Q99J64, Q99MV5

Diamond homologs: O35309, P80217, Q13287, Q3ZCL3, Q9D8C4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

953 predictions. Top by Δscore:

Variant	Effect	Δscore
17:43012176:CAGGC:C	acceptor_loss	1.0000
17:43012177:A:AG	acceptor_gain	1.0000
17:43012177:AG:A	acceptor_gain	1.0000
17:43012178:G:GA	acceptor_gain	1.0000
17:43012178:GG:G	acceptor_gain	1.0000
17:43012178:GGC:G	acceptor_gain	1.0000
17:43012178:GGCC:G	acceptor_gain	1.0000
17:43012274:CAAG:C	donor_loss	1.0000
17:43012275:AAG:A	donor_loss	1.0000
17:43012278:G:GG	donor_gain	1.0000
17:43012278:GT:G	donor_loss	1.0000
17:43012279:T:G	donor_loss	1.0000
17:43013192:AAGGT:A	donor_loss	1.0000
17:43013193:AGGT:A	donor_loss	1.0000
17:43013194:GGTA:G	donor_loss	1.0000
17:43013196:T:G	donor_loss	1.0000
17:43013261:A:AG	acceptor_gain	1.0000
17:43013262:C:G	acceptor_gain	1.0000
17:43013265:A:AG	acceptor_gain	1.0000
17:43013265:AGT:A	acceptor_gain	1.0000
17:43013265:AGTG:A	acceptor_gain	1.0000
17:43013266:G:GA	acceptor_gain	1.0000
17:43013266:GT:G	acceptor_gain	1.0000
17:43013266:GTG:G	acceptor_gain	1.0000
17:43013266:GTGG:G	acceptor_gain	1.0000
17:43013266:GTGGC:G	acceptor_gain	1.0000
17:43013267:T:TA	acceptor_gain	1.0000
17:43013590:A:T	donor_gain	1.0000
17:43013594:G:GT	donor_gain	1.0000
17:43013608:G:GT	donor_gain	1.0000

AlphaMissense

1838 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:43013647:T:C	F183L	0.993
17:43013649:T:A	F183L	0.993
17:43013649:T:G	F183L	0.993
17:43013648:T:C	F183S	0.988
17:43014202:T:C	F255S	0.988
17:43013648:T:G	F183C	0.982
17:43014201:T:C	F255L	0.982
17:43014203:C:A	F255L	0.982
17:43014203:C:G	F255L	0.982
17:43013179:T:C	F85L	0.977
17:43013181:T:A	F85L	0.977
17:43013181:T:G	F85L	0.977
17:43013510:T:A	V137D	0.972
17:43013572:T:C	F158L	0.970
17:43013574:C:A	F158L	0.970
17:43013574:C:G	F158L	0.970
17:43013805:T:C	F198L	0.969
17:43013807:C:A	F198L	0.969
17:43013807:C:G	F198L	0.969
17:43014279:T:C	F281L	0.967
17:43014281:C:A	F281L	0.967
17:43014281:C:G	F281L	0.967
17:43013575:T:C	F159L	0.966
17:43013577:T:A	F159L	0.966
17:43013577:T:G	F159L	0.966
17:43013080:T:C	F52L	0.962
17:43013082:C:A	F52L	0.962
17:43013082:C:G	F52L	0.962
17:43014280:T:C	F281S	0.956
17:43014206:G:C	Q256H	0.955

dbSNP variants (sampled 300 via entrez): RS1000057655 (17:43014740 T>A), RS1000529574 (17:43014481 T>C), RS1000581878 (17:43014940 T>C), RS1001071099 (17:43009558 T>C,G), RS1001216878 (17:43005936 C>T), RS1001335123 (17:43009274 C>T), RS1001514036 (17:43008583 G>A), RS1001697524 (17:43005247 C>T), RS1001732294 (17:43012302 T>C), RS1001994736 (17:43012067 C>A,T), RS1002014565 (17:43005107 TAAC>T), RS1002469298 (17:43010810 C>A,T), RS1002597752 (17:43013494 G>C), RS1002700524 (17:43006734 C>A,T), RS1003279466 (17:43006692 C>A,T)

Disease associations

OMIM: gene MIM:600735 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005194_158	Coronary artery disease	6.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	decreases expression, increases expression	4
Cisplatin	affects cotreatment, increases expression, affects reaction, decreases expression, decreases reaction	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Nickel	decreases expression, increases expression	2
Tretinoin	increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
sotorasib	affects cotreatment, increases expression	1
aminomethylphosphonic acid (AMPA)	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
glycidyl methacrylate	decreases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	decreases expression	1
tamibarotene	increases expression	1
K 7174	decreases expression	1
erastin	decreases reaction, affects reaction, decreases expression	1
tofacitinib	decreases expression	1
nutlin 3	increases expression, affects cotreatment	1
ICG 001	increases expression	1
N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
trametinib	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression, increases expression	1
Temozolomide	increases expression	1
Air Pollutants	decreases expression	1
Air Pollutants, Occupational	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2N9	Abcam A-549 IFI35 KO	Cancer cell line	Male
CVCL_E1D0	Ubigene THP-1 IFI35 KO	Cancer cell line	Male
CVCL_SS13	HAP1 IFI35 (-) 1	Cancer cell line	Male
CVCL_SS14	HAP1 IFI35 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.